Diapositiva 1
Download
Report
Transcript Diapositiva 1
14th World Congress on Gastrointestinal Cancer
San Francisco, CA January 24-26 2013
FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev
as 1st-line treatment of metastatic colorectal cancer:
results of the phase III randomized TRIBE trial
Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V,
Salvatore L, Trenta P, Tomasello G, Ronzoni M, Ciuffreda L,
Zaniboni A, Tonini G, Buonadonna A, Valsuani C, Chiara S,
Carlomagno C, Boni C, Marcucci L, Boni L, Falcone A
on behalf of the GONO Investigators
Disclosures
Bayer, Consultant
Background
Doublets plus bev are a standard of care in the first-line treatment
of mCRC
Hurwitz et al. NEJM ‘04, Saltz et al. JCO ‘08
FOLFOXIRI demonstrated superior RR, PFS and OS compared to
FOLFIRI in a previous phase III trial by the GONO group
Falcone et al. JCO ‘07
FOLFOXIRI plus bev achieved promising results (median PFS 13.1
mos, RR 77%), with a safe toxicity profile in a phase II study (N=57)
Masi et al. Lancet Oncol ‘11
Objective
To confirm the superiority
in the 1st- line treatment of unresectable mCRC
of FOLFOXIRI triplet compared to FOLFIRI doublet
also when bevacizumab is associated to chemotherapy
Study Design
FOLFIRI + bev*
1st line
unresectable
mCRC pts
stratified by
center
PS 0/1-2
adjuvant CT
R
1:1
*both repeated every 2 wks for a max of 12 cycles
followed by maintenance with 5FU/bev until PD
•
Bev 5 mg/kg ev g1
•
Irinotecan 180 mg/sqm ev g1
•
L-LED 200 mg/sqm ev g1
•
5-FU 400 mg/sqm ev g1 bolus
•
5-FU 2400 mg/sqm ev gg13
FOLFOXIRI + bev*
•
Bev 5 mg/kg ev g1
•
Irinotecan 165 mg/sqm ev g1
•
Oxaliplatin 85 mg/sqm ev g1
•
L-LED 200 mg/sqm ev g1
•
5-FU 3200 mg/sqm ev gg13
Treatment schedule
Experimental ARM : FOLFOXIRI + bev
bev
5 mg/Kg
irinotecan
165 mg/sqm
oxaliplatin
85 mg/sqm
L-LV
200 mg/sqm
30 min
1 hour
2 hours
5FU flat continuous infusion
3200 mg/sqm 48h
48 hours
Endpoints
Primary end-point
Progression free survival
Secondary end-points
•
Response Rate
•
Secondary R0-resection rate
•
Overall survival
•
Safety profile
•
Biomarkers evaluation
Statistical considerations
Assuming a median PFS for FOLFIRI plus bev of 11 months
(Kozloff et al. JCO ’09, Sobrero et al. Oncology ‘09)
to detect a HR for PFS of 0.75 in favour of FOLFOXIRI plus bev
with a 2-sided type 1 error: 0.05; power: 80%
379 events required
(approximately 450-500 patients to be randomized)
Key Eligibility Criteria
Histologically proven adenocarcinoma
Unresectable mCRC not previously treated for metastatic disease
At least one measurable lesion according to RECIST 1.0
Age 18-75
ECOG PS ≤ 2 (ECOG PS = 0 if age = 71-75 years)
Adjuvant oxa-containing chemotherapy allowed if more than 12
months elapsed between the end of adjuvant and first relapse
Adequate bone marrow, liver and renal functions
Patients’ demographics – ITT population
N=508
FOLFIRI + bev
N = 256
FOLFOXIRI + bev
N = 252
61 / 39
60 / 40
60 (29 – 75)
61 (29 – 75)
89 / 11
90 / 10
Characteristic, % patients
Sex (M / F)
Median Age (range)
ECOG PS (0 / 1-2)
Baseline disease characteristics – ITT population
FOLFIRI + bev
N = 256
FOLFOXIRI + bev
N = 252
Synchronous Metastases (Y / N)
81 / 19
79 / 21
Prior Adjuvant CT (Y / N)
12 / 88
12 / 88
24 / 70 / 6
35 / 60 / 5
Number Metastatic Sites (1 / >1)
24 / 76
31 / 69
Liver Only Disease (Y / N)
18 / 82
23 / 77
Resected Primary (Y / N)
65 / 35
69 / 31
41 / 44 / 11 / 4
43 / 44 / 7 / 6
Characteristic, % patients
Primary Tumor Site (right / left / NE)
Kohne score (low / interm / high / NE)
Primary endpoint: PFS – ITT population
FOLFIRI + bev
Progression-free survival probability
FOLFOXIRI + bev
Median follow up: 26.6 mos
FOLFIRI + bev: N = 256 / Progressed = 225
FOLFOXIRI + bev: N = 252 / Progressed = 199
FOLFIRI + bev, median PFS : 9.7 mos
FOLFOXIRI + bev, median PFS : 12.2 mos
Unstratified HR: 0.73 [0.60-0.88]
p=0.0012
Stratified HR: 0.71 [0.59-0.86]
p=0.0006
PD-free rate
at 2 years:
11.4% vs 20.3%
F-up time (months)
FOLFIRI/bev
256
198
93
42
22
10
3
0
0
0
FOLFOXIRI/bev
252
203
125
64
27
15
8
3
1
0
Subgroup analyses of PFS
0.5
Experimental better
1
1.5
Control Better
2
Secondary endpoint: Response rate (ITT population)
FOLFIRI + bev
N = 256
FOLFOXIRI + bev
N = 252
Complete Response
3%
4%
Partial Response
50%
61%
Response Rate
53%
65%
Stable Disease
32%
24%
Progressive Disease
5%
2%
Not Assessed
10%
9%
p
Best Response, %
0.006
Target lesions shrinkage: waterfall plots
FOLFIRI + BEV
FOLFOXIRI + BEV
Overall Safety – Safety population
FOLFIRI + bev
N = 254
FOLFOXIRI + bev
N = 250
Serious AEs
19.7%
20.4%
Fatal AEs
3.5%
2.8%
Treatment-related deaths
1.6%
2.4%
Early deaths
(within 60 days from random)
2.7%
3.6%
Patients, %
Toxicity Profile – Safety population
FOLFIRI + bev
N=254
FOLFOXIRI + bev
N=250
p
Nausea
3
3
1.000
Vomiting
3
4
0.492
Diarrhea
11
19
0.012
Stomatitis
4
9
0.048
Neutropenia
20
50
<0.001
Febrile neutropenia
6
9
0.315
Neurotoxicity
0
5
<0.001
Hypertension
2
5
0.157
Venous Thrombosis
6
7
0.593
Arterial Thrombosis
2
1
1.000
Bleeding
1
1
1.000
G3/4 adverse events,
% patients
Treatment duration and management
FOLFIRI + bev
N = 254
FOLFOXIRI + bev
N = 250
12 (1-25)
11 (1-21)
Delayed cycles
6%
16%
Cycles with dose reduction
8%
21%
5-FU relative dose intensity
83%
73%
Irinotecan relative dose intensity
84%
74%
Oxaliplatin relative dose intensity
NA
75%
Induction CT cycles, median (range)
Summary
FOLFOXIRI plus bev compared to FOLFIRI plus bev:
significantly reduced the risk of progression (HR=0.73, p=0.0012)
and PFS benefit was consistent among all analyzed subgroups
significantly increased response rate (65% vs 53%, p=0.005)
increased the incidence of grade 3-4 diarrhea, stomatitis and
neutropenia, but not of febrile neutropenia, serious adverse
events and treatment related deaths
Conclusions
The trial achieved its objective of confirming the superiority of
FOLFOXIRI vs FOLFIRI in terms of PFS, also in combination with bev
FOLFOXIRI plus bev compared to FOLFIRI plus bev moderately
increases specific side effects but the overall safety profile is
acceptable
Based on these results FOLFOXIRI plus bev represents a new
option for the treatment of mCRC patients selected according to
the eligibility criteria of this study
Secondary resections, post-progression treatments and overall
survival analyses are ongoing (follow-up still immature)
Translational biomarker analyses are ongoing
Acknowledgements
PATIENTS
INVESTIGATORS and THEIR 33 CENTERS all over Italy
ANCONA: Cascinu AOSTA: Numico AREZZO: Bracarda AVIANO: Frustaci BRESCIA: Zaniboni
CALTANISSETTA: Vitello CREMONA: Passalacqua CUNEO: Merlano FIRENZE: Ribecco
GENOVA IST: Chiara GENOVA GALLIERA: De Censi LECCE: Lorusso LEGNAGO: Bonetti
LIVORNO: Cappuzzo LUCCA: Baldini MILANO NIGUARDA: Siena MILANO HSR: Villa
MIRANO: Vinante MONZA: Bidoli NAPOLI: Tortora PARMA: Ardizzoni PADOVA: Zagonel
PISA: Falcone, Ricci PIOMBINO: Dargenio PONTEDERA: Allegrini PRATO: Di Leo
REGGIO EMILIA: Boni ROMA GEMELLI: Barone ROMA UMBERTO I: Cortesi
ROMA Campus Biomedico: Tonini SONDRIO: Bertolini TORINO: Ciuffreda VERSILIA: Amoroso
Roche
Special thanks go to:
Dr. CREMOLINI Chiara, Dr. BONI Luca, Dr. MASI Gianluca